Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabay

Showing results (941-950 of 953) with videos related to

Pageof 96
Sort By:
The Lancet. Rheumatology|March 28, 2026
Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort studyPiero Ruscitti, Tanja Stamm, Valentin Ritschl, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 4, 2022
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction ModelingMehreen Soomro, Michael Stadler, Nick Dand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 9, 2025
Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disordersAmber De Visscher, Jarne Beliën, Bert Malengier-Devlies, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|November 23, 2012
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsJosef S Smolen, Monika M Schoels, Norihiro Nishimoto, et al.
Annals of Neurology|March 22, 2025
Neuroimaging Biomarkers for Friedreich Ataxia: A Cross-Sectional Analysis of the TRACK-FA StudyNellie Georgiou-Karistianis, Louise A Corben, Eric F Lock, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Pageof 96

Showing results (941-950 of 953) with videos related to

Sort By:
Pageof 96
The Lancet. Rheumatology|March 28, 2026
Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort studyPiero Ruscitti, Tanja Stamm, Valentin Ritschl, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 4, 2022
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction ModelingMehreen Soomro, Michael Stadler, Nick Dand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 9, 2025
Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disordersAmber De Visscher, Jarne Beliën, Bert Malengier-Devlies, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|November 23, 2012
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsJosef S Smolen, Monika M Schoels, Norihiro Nishimoto, et al.
Annals of Neurology|March 22, 2025
Neuroimaging Biomarkers for Friedreich Ataxia: A Cross-Sectional Analysis of the TRACK-FA StudyNellie Georgiou-Karistianis, Louise A Corben, Eric F Lock, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Pageof 96